Search articles in Biotech News

Found 98 articles

  • Weekly Pharma & Life Science News Round-Up: 23rd –

    Weekly Pharma & Life Science News Round-Up: 23rd – 27th January 2023

    • 27 Jan 2023
    • Editor

    A round-up of the latest news from the Pharma & Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Device sectors from 23rd – 27th January 2023.

  • Ingenza welcomes Ian Shott as its new Executive Ch

    Ingenza welcomes Ian Shott as its new Executive Chairman

    • 26 Jan 2023
    • Editor

    Edinburgh-based Ingenza, a pioneer in engineering biology, is pleased to announce the appointment of Dr Ian Shott CBE, FREng to the board as Executive Chairman. Ian joins Ingenza with over 35 years of experience in the global life science and biotechnology industries.

  • Ferronova secures A$11 million to advance nanotech

    Ferronova secures A$11 million to advance nanotech image-guided cancer therapy

    • 23 Jan 2023
    • Editor

    Australian biotech company Ferronova announced today it has secured a further A$11 million to progress the company’s nanoparticle platform to assist surgeons to more accurately locate and remove malignant cells during treatment of gastrointestinal and brain tumors.

  • Weekly Pharma & Life Science News Round-Up: 16th –

    Weekly Pharma & Life Science News Round-Up: 16th – 20th January 2023

    • 20 Jan 2023
    • Lucy Walters

    A round-up of the latest news from the Pharma & Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Device sectors from 16th – 20th January 2023.

  • Elicio Therapeutics and Angion Enter into Definiti

    Elicio Therapeutics and Angion Enter into Definitive Merger Agreement

    • 18 Jan 2023
    • Editor

    Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entered into a definitive merger agreement with Angion Biomedica Corp (NASDAQ:ANGN) under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction.

  • Kazia Raises A$4.5 Million to Progress R&D Program

    Kazia Raises A$4.5 Million to Progress R&D Programs

    • 17 Jan 2023
    • Editor

    Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce a placement of KZA shares, to institutional and sophisticated investors in Australia, at a price of A$0.11 per share. The placement will raise A$4.5 million (exclusive of costs).

  • MODERNA AND CYTOMX ANNOUNCE STRATEGIC RESEARCH COL

    MODERNA AND CYTOMX ANNOUNCE STRATEGIC RESEARCH COLLABORATION FOR MRNA-BASED CONDITIONALLY ACTIVATED THERAPEUTICS

    • 6 Jan 2023
    • Editor

    Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna's mRNA technologies and CytomX's Probody® therapeutic platform.

  • Immutep Achieves 50% Enrollment Milestone in Rando

    Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer

    • 5 Jan 2023
    • Editor

    Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that it has enrolled and randomised over 50% of the planned 154 patients in the TACTI-003 Phase IIb trial.

  • Weekly Pharma & Life Science News Round-Up: 12th –

    Weekly Pharma & Life Science News Round-Up: 12th – 16th December 2022

    • 16 Dec 2022
    • Lucy Walters

    A round-up of the latest news from the Pharma & Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Device sectors from 12th-16th December 2022.

  • Weekly Pharma & Life Science News Round-Up: 5th –

    Weekly Pharma & Life Science News Round-Up: 5th – 9th December 2022

    • 9 Dec 2022
    • Lucy Walters

    A round-up of the latest news from the Pharma & Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Device sectors from 5th-9th December 2022.

  • Anjarium Biosciences appoints ex-Novartis gene the

    Anjarium Biosciences appoints ex-Novartis gene therapy leader Otmane Boussif, DSc as Chief Technology Officer

    • 8 Dec 2022
    • Editor

    Anjarium Biosciences AG (“Anjarium”), a biotech company focused on creating and delivering a new class of non-viral gene therapies, today announces the appointment of Otmane Boussif, DSc as Chief Technology Officer (CTO).

  • Immutep Announces GMP Manufacturing Process Develo

    Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

    • 7 Dec 2022
    • Editor

    Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced today that a GMP compliant manufacturing process has been established for IMP761, its proprietary preclinical candidate for autoimmune diseases. The 200L scale attained by Northway Biotech will ensure supply of IMP761 for IND-enabling studies and ensuing clinical trials.

  • Entact Bio Launches with $81 Million Series A to D

    Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement

    • 6 Dec 2022
    • Editor

    Entact Bio, the company pioneering the development of precision medicines that enhance the function of key proteins, today announced it has raised $81 million in Series A financing to advance its proprietary Encompass™ platform for developing enhancement-targeting chimeric (ENTAC™) molecules.

  • MODERNA APPOINTS GENERAL MANAGERS IN ITALY AND THE

    MODERNA APPOINTS GENERAL MANAGERS IN ITALY AND THE NETHERLANDS, SUPPORTING COMMERCIAL EXPANSION ACROSS EUROPE

    • 22 Nov 2022
    • Editor

    Moderna, Inc., (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the appointment of General Managers for its commercial subsidiaries in Italy and the Netherlands.

  • Marinomed Biotech AG reports increase in revenues

    Marinomed Biotech AG reports increase in revenues for the first 9 months 2022 and significant business development progress

    • 21 Nov 2022
    • Editor

    Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics, reported today strong financial results for the first nine months of the financial year 2022.

  • Weekly Pharma & Life Science News Round-Up: 14th –

    Weekly Pharma & Life Science News Round-Up: 14th – 18th November

    • 18 Nov 2022
    • Lucy Walters

    A round-up of the latest news from the Pharma & Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Device sectors from 14th-18th November.

  • DAVID JIMÉNEZ JOINS MODERNA AS U.S. GENERAL MANAGE

    DAVID JIMÉNEZ JOINS MODERNA AS U.S. GENERAL MANAGER

    • 18 Nov 2022
    • Editor

    Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the appointment of David Jiménez as General Manager, United States, effective November 21, 2022. Mr. Jiménez will be responsible for commercial efforts in the United States, reporting to Arpa Garay, Moderna's Chief Commercial Officer.

  • Weekly Pharma & Life Science News Round-Up: 7th No

    Weekly Pharma & Life Science News Round-Up: 7th November – 11th November

    • 11 Nov 2022
    • Editor

    A round-up of the latest news from the Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Device sectors from 7th-11th November.

  • Bayer Acquires German Biotech Start-up Targenomix

    Bayer Acquires German Biotech Start-up Targenomix

    • 11 Nov 2022
    • Editor

    Bayer announced today the acquisition of German biotech start-up Targenomix. The spin-off of the Max Planck Institute for Molecular Plant Physiology (MPI MPP) uses novel systems biology and computational life science tools to identify new modes of action for crop protection compounds.

  • Singleron opens a new state-of-the-art laboratory

    Singleron opens a new state-of-the-art laboratory to showcase the latest single cell sequencing technology

    • 7 Nov 2022
    • Editor

    Singleron Biotechnologies, a leader in single cell multi-omics analysis, is happy to announce the opening of their brand-new laboratories in Cologne, Germany, dedicated to showcasing their vast single cell sequencing solutions, from instruments to novel kits tailored for many different research applications.